Trial Profile
Phase III Study of ASP7374-Open-label Study of Subcutaneous Vaccination of Quadrivalent ASP7374 in Adult Subjects Aged 20 or Older
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Aug 2020
Price :
$35
*
At a glance
- Drugs Influenza virus RIV3 vaccine-(FluBlok) (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors Astellas Pharma; UMN Pharma
- 28 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Feb 2015 New trial record